金健米業(600127.SH):金健藥業公司已向公司支付餘款約1.19億元
格隆匯12月20日丨金健米業(600127.SH)發佈關於掛牌轉讓湖南金健藥業有限責任公司100%股權的後續公告,按照《長沙市產權交易合同》的約定,結合天健會計師事務所(特殊普通合夥)出具的《關於湖南金健藥業有限責任公司過渡期淨資產變動情況的專項審計報告》(天健湘審〔2019〕148號),扣除金健藥業公司在過渡期內的損益金額-845.81萬元後,截至公告日,金健藥業公司已向公司支付了餘款約1.19億元。至此,公司已收回金健藥業公司的全部欠款。
此次餘款的收回將導致公司本年度經營活動產生的現金流增加1.19億元,具體處理須以會計師年度審計確認後的結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.